Core Insights - Nykredit Group's H1 Interim Report for 2025 reflects a strong financial performance, with a profit after tax of DKK 6,257 million and an upgraded full-year profit guidance of DKK 11.00-12.00 billion, driven by robust core business performance and customer growth [2][3] Financial Performance - Net interest and fee income for the Nykredit Group totaled DKK 7,874 million, with Spar Nord contributing DKK 325 million; excluding Spar Nord, the net interest and fee income was DKK 7,549 million [2][3] - Total income for the Nykredit Group increased to DKK 11,977 million in H1 2025, up DKK 715 million from DKK 11,262 million in H1 2024 [5] - Costs rose to DKK 4,315 million, an increase of DKK 990 million compared to DKK 3,325 million in H1 2024, with transaction and integration costs related to Spar Nord amounting to DKK 763 million [5] Lending and Market Position - Nykredit Group's bank lending reached DKK 177.2 billion, with Spar Nord contributing DKK 64.6 billion; excluding Spar Nord, bank lending increased by 15.8% from DKK 97.4 billion in June 2024 to DKK 112.8 billion in June 2025 [7] - Totalkredit's mortgage lending grew to DKK 934.9 billion at the end of June 2025, up 5.5% from DKK 886.2 billion at the end of June 2024 [7] Customer and Market Strategy - The merger between Nykredit Bank and Spar Nord is on track for completion in spring 2026, aiming to create a customer-owned alternative to larger listed banks [3] - Nykredit's strategy emphasizes partnerships to enhance service offerings and competitive positioning in financial markets [3]

Core Insights - Nykredit Group's H1 Interim Report for 2025 reflects a strong financial performance, with a profit after tax of DKK 6,257 million and an upgraded full-year profit guidance of DKK 11.00-12.00 billion, driven by robust core business performance and the acquisition of Spar Nord [2][3]. Financial Performance - The Nykredit Group reported net interest and fee income of DKK 7,874 million in H1 2025, with Spar Nord contributing DKK 325 million [2]. - Total income for the Nykredit Group reached DKK 11,977 million, an increase of DKK 715 million compared to H1 2024 [5]. - Costs for the Nykredit Group were DKK 4,315 million, up DKK 990 million from the previous year, including DKK 763 million in transaction and integration costs related to Spar Nord [5]. - Profit before tax for the period was DKK 7,432 million, a decrease of DKK 716 million from H1 2024 [5]. Lending and Market Position - Nykredit Group's bank lending totaled DKK 177.2 billion, with Spar Nord contributing DKK 64.6 billion; excluding Spar Nord, bank lending increased by 15.8% year-over-year [7]. - Totalkredit's mortgage lending grew to DKK 934.9 billion, representing a 5.5% increase from the previous year [7]. - The Nykredit Group's cost/income ratio was 32.5% excluding ordinary costs of Spar Nord and 36.0% including them [7]. Strategic Developments - The merger between Nykredit Bank and Spar Nord is on track to be completed by spring 2026, aiming to create a strong customer-owned alternative to larger listed banks [3]. - Nykredit's strategy emphasizes partnerships to enhance service offerings and competitive positioning in financial markets [3].

Sampo plc, stock exchange release, 13 August 2025 at 8:30 am EEST Sampo plc’s share buybacks 12 August 2025 On 12 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 4,6209.79AQEU 129,4559.77CEUX 40,2309.77TQEX 156,0759.76<td style="width:5cm;;border-right: solid black 1pt ; b ...

The members of the Management Board of AB Artea bankas Daiva Šorienė and Donatas Savickas are leaving the bank. August 14, 2025, is the last day of Donatas Savickas as a member of the board and as Chief Financial Officer (CFO) and of Daiva Šorienė as a member of the board and as Head of Corporate Client Division. "Daiva Šorienė and Donatas Savickas both have played a very important role in creating a modern, responsible, customer-oriented bank. On behalf of the entire Artea Bank Group, I would like to thank ...

Martela Corporation, Half year report, 13.8.2025, at 08:00 a.m. The revenue and operating result for January-June 2025 improved compared to the same period of the previous year. Operating result turned profitable in April-June 2025. April–June 2025 Revenue was EUR 24.6 million (21.0), representing a change of 17.0% Operating result was EUR 0.1 million (-1.6)Operating profit per revenue was 0.5% (-7.7%)The result for the period was EUR -0.4 million (-2.1)Earnings per share amounted to EUR -0.09 (-0.45) Janu ...

Core Insights - Santhera Pharmaceuticals has signed an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. for the distribution and promotion of AGAMREE® (vamorolone) in Turkey for treating Duchenne muscular dystrophy (DMD) in patients aged four and older [1][2] - The supply and sales by GEN are expected to commence in the first half of 2026, starting with named patient sales followed by commercial sales [1] - Santhera will receive a small upfront payment and an ongoing percentage of net sales as per previous agreements [1] Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing innovative medicines for rare neuromuscular diseases with high unmet medical needs [7] - AGAMREE® (vamorolone) is a dissociative steroid with a novel mode of action, approved in multiple regions including the U.S., EU, UK, China, and Hong Kong for the treatment of DMD [7][9] - The company has out-licensed rights to AGAMREE for North America and certain Southeast Asian countries [9] Product Information - AGAMREE is designed to bind to the same receptor as glucocorticoids but modifies its downstream activity, potentially dissociating efficacy from steroid safety concerns [3] - In the pivotal VISION-DMD study, AGAMREE met the primary endpoint of Time to Stand (TTSTAND) velocity versus placebo with a p-value of 0.002 at 24 weeks, demonstrating a good safety and tolerability profile [4] - Unlike corticosteroids, AGAMREE shows no restriction of growth and has no negative effects on bone metabolism [5] Partner Company Overview - Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. is Turkey's leading specialty pharmaceutical company, focusing on innovative therapies for neurological and neuromuscular disorders since 1998 [10] - GEN has a GMP-certified facility and invests in original drug development through dedicated R&D centers [10]

Core Viewpoint - Sp Mortgage Bank Plc and the Savings Banks Group have published their Half-Year Financial Report for January to June 2025, along with the Pillar III Disclosure Report as of June 30, 2025, indicating ongoing financial transparency and regulatory compliance [1]. Group 1: Financial Reports - The Half-Year Financial Report covers the period from January 1 to June 30, 2025, providing insights into the financial performance of Sp Mortgage Bank Plc and the Savings Banks Group [2]. - The Pillar III Disclosure Report as of June 30, 2025, is also made available, which is essential for understanding the capital adequacy and risk management practices of the Savings Banks Group [2]. Group 2: Company Structure and Role - Sp Mortgage Bank Plc is part of the Savings Banks Group and the Savings Banks Amalgamation, playing a crucial role in obtaining funding from money and capital markets [1]. - The bank is responsible for mortgage-secured funding for the Savings Banks Group by issuing covered bonds, highlighting its importance in the financial ecosystem [1].

Central Bank of Savings Banks Finland Plc Stock Exchange Release 13 August 2025 at 8:00 am (CET +1) Central Bank of Savings Banks Finland Plc's and Savings Banks Group's Half year financial report for January-June 2025 and Pillar III Disclosure Report 30 June 2025 has been published. The materials are available at www.saastopankki.fi. CENTRAL BANK OF SAVINGS BANKS FINLAND PLC Additional information: Kai Koskela, Managing Director Savings Banks Union Coop kai.koskela@saastopankki.fi +358 40 549 0430 ...

Group 1 - Lerøy Seafood Group ASA will present its Q2 2025 results on 20 August 2025 at Scandic Flesland Airport hotel in Bergen at 08:45 CET during the event "Vestland på Børs" [1] - The presentation will be conducted in Norwegian and will include a Q&A session [1] - The quarterly report and presentation will be published at 06:30 CET on the same day [1] Group 2 - An English recording of the presentation will be available from 13:15 CET on the company's investor website [2] - This information is subject to the disclosure requirements under Section 5-12 of the Norwegian Securities Trading Act [2]

Core Insights - The Feintool Group's business performance in the first half of 2025 reflects a challenging market environment in the automotive sector, particularly in Europe, but the company's strategy is showing positive effects [1][3][18] - Sales declined by 14.2% to CHF 334.5 million, with a local currency decline of 11.5% [5][20] - The operating result (EBIT) before one-off costs was CHF -0.8 million, indicating a slight improvement in profitability despite lower sales [6][20] Financial Performance - The Group generated sales of CHF 334.5 million, down CHF 55.5 million or 14.2% from CHF 390.0 million in H1 2024 [5][20] - The reported operating result (EBIT) after one-off costs was CHF -1.9 million, compared to CHF 0.2 million in H1 2024 [6][20] - The net result for the first half of 2025 was CHF -5.0 million, a decline of 56.1% from CHF -3.2 million in the previous year [20] Regional Performance - In Europe, sales were CHF 199.6 million, down 17.5% from CHF 241.8 million in H1 2024, primarily due to weak demand for electric vehicles [9][20] - Sales in the US were CHF 98.0 million, a decrease of 7.3% from CHF 105.7 million in H1 2024, attributed to lower raw material prices and a weak US dollar [15][20] - Sales in Asia were CHF 38.5 million, down 12.5% from CHF 44.0 million in H1 2024, impacted by falling exports from Japan and competition in the Chinese automotive market [12][20] Strategic Initiatives - Feintool's strategy of focusing on three core technologies and a global manufacturing network is proving effective, particularly in fineblanking and forming technologies [3][4] - The company is expanding its presence in Asia, with a new plant in Pune, India, set to start operations in 2026 [14][18] - The restructuring of production for electric motor components in Germany is underway, expected to improve profitability by 2027 [10][11] Market Outlook - The outlook for the second half of 2025 is cautious, with expectations of continued challenges in the European market [18] - Medium-term optimism is based on global megatrends towards low-carbon energy generation and mobility, which present significant opportunities for Feintool's technologies [19][22]